1. Scrip
  2. >>Business

Will Sanofi Overpay For Actelion Innovation Or, Like J&J, Also Walk Away?

 
• By Sten Stovall

Reported M&A talks between Sanofi and Actelion will likely stand or fall on the former's willingness to overpay and the target's demanded price for surrendering its independence.

Johnson & Johnson has walked away and Sanofi has reportedly taken its place in talks for a deal with Actelion Pharmaceuticals Ltd. that, if consummated, could value the Swiss pulmonary arterial hypertension specialist at up to an eye-watering $30bn.

It was less than two months ago that Sanofi's CEO Olivier Brandicourt said the French group would consider a mid-sized bolt-on attempt if the opportunity arose that can bring it value and further aid Sanofi's quest to diversify into promising therapy areas. (Also see "Sanofi CEO Upbeat Despite Medivation M&A Miss, Sarilumab Diss" - Scrip, 31 October, 2016

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Business

More from Scrip

Sarepta Slammed By Double Blow: Elevidys Sales Miss, Prasad’s CBER Appointment

 
• By Mandy Jackson

Sarepta’s stock price was battered after Vinay Prasad was appointed to lead the US FDA’s CBER, then the company’s shares were bruised when Q1 Elevidys sales came in below consensus.

Marea Eyes Cardioprotective Benefit With ANGPTL4 Inhibition

 
• By Joseph Haas

Phase IIa data for ANGPTL4-targeted antibody shows reduced triglycerides and remnant cholesterol, which Marea asserts indicates potential to protect against cardiovascular outcomes.

BeiGene To Trade Beach For Chalet In Swiss Redomiciling As BeOne

 
• By Alaric DeArment

The biotech saw a slight quarter-over-quarter decline in sales from the BTK inhibitor Brukinsa, which it attributed to seasonality, while revenues overall missed some analyst estimates.